This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
A first of its kind "self-blinded" trial testing the effect of psychedelic microdosing has found the anecdotally popular practice may be an example of a strong placebo effect.
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.